TOBORINONE

Details

Stereochemistry	RACEMIC
Molecular Formula	C21H24N2O5
Molecular Weight	384.4257
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

COC1=CC=C(CNCC(O)COC2=CC3=C(NC(=O)C=C3)C=C2)C=C1OC

InChI

InChIKey=BYKYPZBCMBEEGU-UHFFFAOYSA-N

InChI=1S/C21H24N2O5/c1-26-19-7-3-14(9-20(19)27-2)11-22-12-16(24)13-28-17-5-6-18-15(10-17)4-8-21(25)23-18/h3-10,16,22,24H,11-13H2,1-2H3,(H,23,25)

HIDE SMILES / InChI

Molecular Formula	C21H24N2O5
Molecular Weight	384.4257
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description
Sources: http://www.ncbi.nlm.nih.gov/pubmed/11060731
Curator's Comment: description was created based on several sources, including: DOI: 10.1111/j.1527-3466.1995.tb00306.x http://www.ncbi.nlm.nih.gov/pubmed/18465598

Toborinone is an inotropic agent. Positive inotropic effects are produced by Phosphodiesterase inhibition with resulting increase in cAMP and intracellular calcium levels. There is also marked venous and arterial vasodilating properties. With regards to human administration, toborinone is generally well-tolerated, though there are no available data regarding long-term tolerability and side effects. Toborinone can be combined with angiotensin-converting-enzyme inhibitors, nitrates and diuretics for the treatment of heart failure.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Phosphodiesterase 3 60 Target ID: CHEMBL2094125 Sources: http://www.ncbi.nlm.nih.gov/pubmed/11060731	Inhibitor 8297

Conditions

Condition	Modality	Targets	Highest Phase	Product
Heart failure 103 Sources: http://www.ncbi.nlm.nih.gov/pubmed/18465598 http://adisinsight.springer.com/drugs/800002217	Primary		Approved 8429	Toborinone Approved Use Toborinone is used to treat heart failure.

PubMed

Title	Date	PubMed
Toborinone Otsuka Pharmaceutical Co Ltd.	1998 Sep	18465598
Clinical overview of the novel inotropic agent toborinone.	2000 May	11060731
Toborinone and olprinone, phosphodiesterase III inhibitors, inhibit human platelet aggregation due to the inhibition of both calcium release from intracellular stores and calcium entry.	2004	15127258

Patents

Sample Use Guides

In Vivo Use Guide

Patients received 1.25, 2.5, 5 or 10 ug/kg/min toborinone via a 6-h infusion.

Route of Administration: Other

In Vitro Use Guide

9.7 uM of Toborinone inhibits human platelet aggregation.

Substance Class	Chemical Created by `admin` on `Fri Dec 15 18:44:16 GMT 2023` Edited by `admin` on `Fri Dec 15 18:44:16 GMT 2023`
Record UNII	1U1N0YXM99
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

TOBORINONE

Official Name

English

OPC-18790

Code

English

Toborinone [WHO-DD]

Common Name

English

TOBORINONE [USAN]

Common Name

English

TOBORINONE [JAN]

Common Name

English

toborinone [INN]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C744